Estrigenix is developing a proprietary selective estrogen receptor‑beta (ERβ) platform intended to modulate ERβ biology with selective, non‑steroid approaches. The company aims to apply this platform across multiple women's health and neurodegenerative indications that share the ERβ biological pathway. Recent corporate milestones include completion of an exclusive IP license and the appointment of Victoria Zellmer as CEO, alongside ongoing preclinical progress. Estrigenix announced the first closing of a $2M Series Seed financing led by Talents Fund I to fund lead optimization and completion of its translational preclinical package. The financing is intended to position its lead programs for IND‑enabling studies and future clinical development, and the company has reported interest from multiple pharmaceutical companies in its lead candidate.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026